Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-DTPA-NLS-CSL360
- Development stage
- Preclinical
- Lead developer
- CSL
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**111In-DTPA-NLS-CSL360** is a preclinical, Auger electron-emitting radioimmunoconjugate for **acute myeloid leukemia**. It comprises the chimeric anti-CD123 monoclonal antibody CSL360, conjugated to diethylenetriaminepentaacetic acid for chelation of indium-111 and modified with SV40-derived nuclear localization sequence peptides. The agent preferentially recognizes the CD123-positive and CD131-negative leukemia stem-cell phenotype, undergoes cellular internalization and nuclear transport, and delivers short-range Auger-electron radiation that induces lethal DNA damage. It has been evaluated in AML cell models and AML-engrafted immunodeficient mice, including studies of radioimmunotherapy and microSPECT imaging. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S096980431530378X))
- Other names
- (111)In-DTPA-NLS-CSL360
02
Targets
IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on 111In-DTPA-NLS-CSL360.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-DTPA-NLS-CSL360.